Liquid Embolic Market Research Report By Therapeutic Modality (N-Butyl Cyanoacrylate (NBCA), Ethylene Vinyl Alcohol Copolymer (Onyx), Polyvinyl Alcohol (PVA)), By Application (Arteriovenous Malformations (AVMs), Dural Arteriovenous Fistulas (DAVFs), Carotid Cavernous Fistulas (CCFs)), By End User (Hospitals, Ambulatory Surgical Centers (ASCs), .Neurointerventional Centers) and By Regional (North America, Europe, South America, Asia-Pacific, Middle East and Africa)- Forecast to 2032

Liquid Embolic Market Overview

As per MRFR analysis, the Liquid Embolic Market Size was estimated at 7.49 (USD Billion) in 2022.

The Liquid Embolic Market Industry is expected to grow from 8.07(USD Billion) in 2023 to 15.7 (USD Billion) by 2032. The Liquid Embolic Market CAGR (growth rate) is expected to be around 7.68% during the forecast period (2024 - 2032).

Key Liquid Embolic Market Trends Highlighted

The Liquid Embolic market is evolving due to new technologies and increasing use cases in many areas of medicine. One of the trends that can be mentioned is the growing use of neurovascular embolization for patients with cerebral aneurysms and arteriovenous malformations (AVMs). This growth is because of the effectiveness and minimally invasive nature of these procedures.

Moreover, the availability of newer embolic agents that have improved biocompatibility, targeting, and release properties creates prospects for market growth. Also, the rising incidences of vascular diseases such as peripheral artery disease and uterine fibroids are forcing the push for liquid embolic to be used rather than liquid embolic rather than other surgery methods.

The other trend nowadays is the introduction of precision embolization, the ability to deliver an embolic agent to an exact point in a specific body part during a procedure. This allows for better results to be achieved with fewer risks. In general, the Liquid Embolic market is expected to grow further as more innovations in medical devices and treatment approaches can provide better ways to manage different diseases.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Liquid Embolic Market Drivers

Rising Prevalence of Vascular Malformations and Neurological Disorders

The rising prevalence of vascular malformations and neurological disorders is a major driver of growth in the Liquid Embolic Market Industry. Vascular malformations are abnormal connections between blood vessels that can occur anywhere in the body, while neurological disorders are conditions that affect the nervous system. Both of these conditions can cause a variety of symptoms, including pain, swelling, and neurological deficits. Liquid embolic agents are used to treat these conditions by blocking off the affected blood vessels or by providing a scaffold for the formation of new blood vessels.This growth will be driven by the rising prevalence of vascular malformations and neurological disorders, as well as the increasing awareness of liquid embolic agents and their benefits.

Technological Advancements

Another key driver of growth in the Liquid Embolic Market Industry is technological advances. Over the past few years, there have been multiple significant achievements in the development of liquid embolic agents. The application of technological advancements has led to the creation of agents that are more efficacious, less invasive, and easier to use. One of the most significant technological advancements in the development of LEB agents is microspheres.These are small, round particles made from a variety of different materials, including polymers, metals, and ceramics. They can be injected into the bloodstream and then guided to specific locations of the body. When in place, microspheres can block off blood vessels or serve as a scaffold for the construction of new blood vessels. Despite being highly efficacious in blocking off vessels, microspheres are less invasive and easier to use and, therefore, are rapidly gaining popularity in the treatment of vascular malformations and different neurological issues.

Growing Demand for Minimally Invasive Procedures

The growing demand for minimally invasive procedures is also contributing to the growth of the Liquid Embolic Market Industry. Minimally invasive procedures are surgical procedures that are performed through small incisions. These procedures are less invasive than traditional open surgery, and they offer a number of benefits, including reduced pain, scarring, and recovery time. Liquid embolic agents can be used in a variety of minimally invasive procedures.For example, liquid embolic agents can be used to treat vascular malformations and neurological disorders. In these procedures, liquid embolic agents are injected into the affected blood vessels or the surrounding tissue. The liquid embolic agents then block off the blood vessels or provide a scaffold for the formation of new blood vessels. The growing demand for minimally invasive procedures is expected to continue to drive the growth of the Liquid Embolic Market Industry in the coming years.

Liquid Embolic Market Segment Insights

Liquid Embolic Market Therapeutic Modality Insights  

N-butyl cyanoacrylate (NBCA), Ethylene Vinyl Alcohol Copolymer (Onyx), and Polyvinyl Alcohol (PVA) are the three primary therapeutic modalities employed in liquid embolic procedures. NBCA is a fast-acting liquid embolic agent widely used for the treatment of hypervascularized tumors and arteriovenous malformations due to its rapid polymerization upon contact with ionic solutions. It offers precise embolization and minimal tissue damage, making it suitable for embolizing small and medium-sized vessels. Onyx, a copolymer of ethylene and vinyl alcohol, is a non-adhesive liquid embolic agent known for its ability to penetrate deeply into vascular structures.Its high viscosity allows for controlled deployment and conformability, making it ideal for embolizing larger vessels and irregular vascular networks. Onyx is commonly used in the embolization of cerebral aneurysms, dural arteriovenous fistulas, and spinal vascular malformations. PVA is a water-soluble liquid embolic agent with excellent biocompatibility and minimal inflammatory response. It is often used in combination with other embolic agents to achieve a more complete and durable embolization. PVA is particularly useful for embolizing larger vessels and cavities, such as uterine fibroids, varicoceles, and arteriovenous malformations.These three therapeutic modalities collectively represent a significant portion of the Liquid Embolic Market revenue. The market for NBCA is projected to grow at a steady pace, driven by its widespread adoption in neurovascular and peripheral embolizations. Onyx is expected to witness a robust growth rate due to its increasing use in complex neurovascular procedures. PVA is anticipated to gain popularity in the embolization of larger vessels and cavities, contributing to the overall growth of the therapeutic modality segment. Understanding the specific characteristics, applications, and growth potential of each therapeutic modality is crucial for manufacturers and healthcare providers to make informed decisions regarding product development, treatment strategies, and market positioning.By leveraging this data, stakeholders can effectively address the evolving needs of patients and capitalize on the opportunities presented by the Liquid Embolic Market.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Liquid Embolic Market Application Insights  

Arteriovenous malformations, dural arteriovenous fistulas, and carotid cavernous fistulas are all conditions that can be treated with liquid embolic agents. Arteriovenous malformations are abnormal connections between arteries and veins, dural arteriovenous fistulas are abnormal connections between arteries and veins in the dura mater, and carotid cavernous fistulas are abnormal connections between the carotid artery and the cavernous sinus. This is due to the rising incidence of these conditions, as well as the increasing use of liquid embolic agents in treatment.Arteriovenous malformations are the most common type of cerebrovascular malformation, accounting for approximately 50% of all cases. Dural arteriovenous fistulas are a rare type of literature review cerebrovascular malformation, accounting for approximately 10% of all cases. Carotid cavernous fistulas are the least common type, accounting for around 5% of all cases. The treatment for all three conditions usually involves either surgery, embolization, or both. Surgical or embolic procedures are increasingly being used for their embolization, as they can occlude the blood vessels and stop the bleeding.The Liquid Embolic Market for these conditions is very competitive, with many of the major players being involved in the market. Some of the major players in the industry are Boston Scientific Corporation, Johnson & Johnson, and Medtronic plc.

Liquid Embolic Market End User Insights  

The Liquid Embolic Market Segmentation by End User into Hospitals, Ambulatory Surgical Centers (ASCs), and Neurointerventional Centers offers valuable insights into the industry dynamics. Hospitals dominate the market, accounting for a significant share of the Liquid Embolic Market revenue due to the high volume of embolization procedures performed in these settings. Ambulatory Surgical Centers (ASCs) are gaining traction as they provide cost-effective and convenient options for patients. Neurointerventional centers specializing in minimally invasive treatments for neurological disorders are expected to witness steady growth driven by the rising prevalence of conditions like stroke and brain tumors.These segments collectively contribute to the overall growth of the Liquid Embolic Market, influenced by factors such as technological advancements, increasing patient awareness, and expanding healthcare infrastructure.

Liquid Embolic Market Regional Insights  

The Liquid Embolic Market is segmented into North America, Europe, APAC, South America, and MEA. North America is the largest market for liquid embolic agents, followed by Europe. The growth of the North American market is attributed to the increasing prevalence of vascular diseases, the rising demand for minimally invasive procedures, and the growing adoption of advanced embolic agents. The European market is also growing steadily, driven by the increasing awareness of liquid embolic agents and the growing number of endovascular procedures.The APAC market is expected to witness significant growth in the coming years, owing to the rising incidence of vascular diseases and the growing healthcare expenditure in the region. The South American and MEA markets are also expected to grow at a healthy pace, driven by the increasing adoption of liquid embolic agents and the growing number of endovascular procedures.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Liquid Embolic Market Key Players And Competitive Insights

Major players in the Liquid Embolic Market industry are constantly striving to gain a competitive edge by investing in research and development, expanding their product portfolios, and acquiring smaller players. Leading Liquid Embolic Market players are focusing on developing innovative products that cater to the evolving needs of healthcare providers and patients. The increasing prevalence of vascular diseases, technological advancements, and rising healthcare expenditure drive the Liquid Embolic Market development. The Liquid Embolic Market Competitive Landscape is expected to remain highly competitive, with new entrants and established players vying for market share.Medtronic, a leading company in Liquid Embolic Market, offers a broad range of liquid embolic products for various clinical applications. The company's portfolio includes Onyx, a non-adhesive liquid embolic system that is widely used for embolizing brain aneurysms and arteriovenous malformations. Medtronic also provides technical support and training to healthcare professionals to ensure optimal outcomes. The company's strong brand recognition, extensive distribution network, and commitment to innovation contribute to its leadership position in the market.Boston Scientific, a prominent competitor in Liquid Embolic Market, offers a comprehensive portfolio of liquid embolic for diverse medical specialties, including interventional radiology, neurology, and oncology. The company's flagship product, Embosphere Microspheres, is a biocompatible and bioresorbable embolic agent used for embolizing hypervascular tumors and controlling bleeding. Boston Scientific is dedicated to advancing liquid embolization techniques through research and development, expanding its global presence, and collaborating with healthcare professionals to improve patient care.

Key Companies in the Liquid Embolic Market Include

• Guerbet


• Medtronic


• Penumbra, Inc.


• Stryker


• Balt Extrusion


• Cardinal Health


• Cook Medical


• Cerenovus


• Merit Medical Systems, Inc.


• Terumo Corporation


• Microvention


• DePuy Synthes


• Boston Scientific Corporation


• Johnson Johnson


• Codman Shurtleff, Inc.

Liquid Embolic Market Industry Developments

The Liquid Embolic Market is projected to reach USD 15.7 billion by 2032, exhibiting a CAGR of 7.68% during the forecast period (2024-2032). The increasing prevalence of vascular malformations and the rising demand for minimally invasive procedures are key factors driving market growth. Technological advancements, such as the development of biocompatible and biodegradable embolic agents, are further fueling market expansion. Strategic collaborations and acquisitions among market players are also shaping the competitive landscape. Recent news developments include the FDA approval of Embozene Microspheres for embolization procedures and the acquisition of Neuravi by Stryker, reflecting the growing focus on innovation and consolidation in the market.

Liquid Embolic Market Segmentation Insights

Liquid Embolic Market Therapeutic Modality Outlook

• N-Butyl Cyanoacrylate (NBCA)


• Ethylene Vinyl Alcohol Copolymer (Onyx)


• Polyvinyl Alcohol (PVA)

Liquid Embolic Market Application Outlook

• Arteriovenous Malformations (AVMs)


• Dural Arteriovenous Fistulas (DAVFs)


• Carotid Cavernous Fistulas (CCFs)

Liquid Embolic Market End User Outlook

• Hospitals


• Ambulatory Surgical Centers (ASCs)


• Neurointerventional Centers

Liquid Embolic Market Regional Outlook

• North America


• Europe


• South America


• Asia-Pacific


• Middle East and Africa